1Investors - Qualified investors are defined as institutional, private equity, angel and venture investors with funds on-hand, whose primary activity is direct investment in research and development companies (e.g., hedge fund, mutual fund, or venture fund). Equity research analysts from investment banking institutions and buy-side analysts also qualify as investors.
2Government/Academic/Non-Profit - Attendees affiliated with accredited government or academic institution. Attendees must show proof through business card or ID on-site. To be eligible for the non-profit registration category, the attendee must show proof of working for an organization that has already received 501(c)(3) status from the U.S. Internal Revenue Service. Please send your request to BIO Registration.
3Presentation Fees - Presentation fees include the basic registration fee. Your presentation fee is not due until your application to present has been accepted. A presentation code is required. Please send an e-mail to Emily Longvall to request a unique registration code.
4Discovery Attendee - This year’s BIO Asia event will feature a series of Discovery presentations. A pricing level has been created for “pre-emerging” biotech companies wishing to participate in the BIO Asia International Conference. The presentations will focus on early-stage companies that are first-time presenters at this event and use biotechnology for research and development of human health drug products or diagnostics. Discovery companies must have been founded after January 2016, and be raising venture capital. The typical audience for all presentations features business development executives from large pharma and biotech companies, as well as venture investors. Companies interested in qualifying for the Discovery rate should contact Emily Longvall.
5Corporations qualifying for the Discovery company rates include only the following: Discovery companies are "pre-emerging" biotech companies, qualifying as seed and A-round companies founded after January 2016, and be raising venture capital. For this event, Discovery companies must use biotechnology or related technologies for research and development of human health drug products or diagnostics. Approval is required to register for this category.
6Biotech/Pharma Company - Corporations or other entities that use biotechnology or related technologies for research and development of products or information.